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A guanidine-appended scyllo-
inositol derivative AAD-66 
enhances brain delivery and 
ameliorates Alzheimer’s 
phenotypes
Dohyun Lee1, Woo-Sirl Lee2, Sungsu Lim4, Yun Kyung Kim4, Hoe-Yune Jung  3,5, Sanket Das2, 
Juhyun Lee3, Wenjie Luo6, Kyong-Tai Kim  1,3 & Sung-Kee Chung2
Alzheimer’s disease (AD) is a degenerative brain disease that destroys memory and other important 
mental functions but lacks efficient therapeutic agents. Blocking toxic amyloid β (Aβ) could be 
beneficial for AD and represents a promising therapeutic strategy for AD treatment. scyllo-Inositol 
(SI) is a potential therapeutic for AD by directly interacting with the Aβ peptide to inhibit Aβ42 fiber 
formation. Clinical studies of SI showed promising benefits on mild to moderate AD, however, with 
limitations on dosage regime. A new strategy to enhance the brain delivery of SI is needed to achieve 
the efficacy with minimum adverse effects. Herein, we report that a novel guanidine-appended SI 
derivative AAD-66 resulted in more effective reductions of brain Aβ and plaque deposits, gliosis, and 
behavioral memory deficits in the disease-established 5xFAD mice. Overall, our present study reveals 
the potential of AAD-66 as a promising therapeutic agent for AD.
Alzheimer’s disease (AD) is the most common type of dementia. It is prevalent worldwide with approximately 
46.8 million patients, and the incidence increases rather rapidly because there is no available cure and the aging 
population is continuously increasing1. AD brains are characterized by two pathological hallmarks, amyloid β 
(Aβ) plaques and neurofibrillary tangles, which are tightly associated with neuronal damage and disease progres-
sion2–4. Preventing or blocking formation of neuronal toxic Aβ oligomers represents one of promising therapeutic 
strategies for AD. Among the several potential therapeutic agents for AD, scyllo-inositol (SI) has been reported to 
effectively block oligomerization of Aβ peptides in vitro, reduce Aβ plaques in vivo, and alleviate symptoms of AD 
in a mouse model5–7. It was reported that SI concentrations in the cerebrospinal fluid (CSF) and brain increased 
after its administration, and its preclinical data supported that a sustained elevated level of SI in the brain seemed 
necessary for the therapeutic efficacy6–9. Thus, SI has been clinically studied for the treatment of AD. The results 
indicated potential benefits on the earlier stage AD patients, but its clinical use was not recommended because 
of serious adverse effects in the higher dose groups10,11. The adverse effects at high dose may be attributed to 
the renal function overloaded with systemically increased levels of SI and suffered from hyperuricemia11–13. So 
increasing brain penetrating efficiency of SI could lower the SI dosage and improve SI efficacy for AD treatment 
while minimizing the adverse events.
In the present study, we have utilized our recently developed novel brain delivery system based on 
guanidine-rich molecular carriers to increase SI brain levels. Novel guanidine-rich molecular carriers showed 
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excellent blood-brain-barrier (BBB) permeability and they successfully improved the efficacies of brain cancer 
treatment in mouse models after conjugation to several anti-cancer drugs including doxorubicin, 5-fluorouracil, 
and paclitaxel14–19. More recently, trehalose, an anti-aggregation agent on Huntington’s disease (HD), demon-
strated improved BBB crossing efficiency with multiple guanidine (appendages) and increased neuroprotective 
effects20. We report herein that one of our guanidine-appended SI derivatives AAD-66, which has a good BBB 
crossing ability, improved efficacies on reducing brain pathologies as well as cognitive deficits in 5xFAD AD 
transgenic mice.
Results
Preparing the guanidine-appended SI derivative AAD-66. As guanidine-rich molecular carriers14–17 
and the guanidine-appended modifications20 were found to enhance the cell membrane-crossing ability and the 
BBB permeability, we have prepared the guanidine-appended derivatives of SI (Fig. 1, Supplementary Methods). 
The synthetic design involves linking the hydroxyl groups of SI with guanidine-containing carboxylate chains via 
ester bonds. The ester bonds are expected to be susceptible to cleavage by intracellular esterases. The fluorescein 
isothiocyanate (FITC) attached SI derivatives were examined for the cellular membrane and the BBB penetration 
abilities. In the preliminary experiments with fluorescent microscopy and FACS analysis, AAD-56-FITC, which 
carries five guanidine groups together with one FITC group, showed a good efficiency in crossing cellular mem-
branes and the BBB (Supplementary Fig. S1).
Oral administration of AAD-66 effectively ameliorates cognitive deficits in 5xFAD mice. Oral 
administration of SI was previously reported to reverse the established AD phenotypes in an AD mouse model6,7. 
We, therefore, tested the efficacy of AAD-66, a SI derivative containing six guanidine groups, by oral administra-
tion at the symptomatic age of 5xFAD mice (Fig. 2A). This transgenic (Tg) mouse model expresses five human 
Figure 1. Structure of scyllo-inositol and its derivative AAD-66. (A) Schemes for the synthesis of the scyllo-
inositol derivative AAD-66. 1, scyllo-inositol. 2, AAD-66. (B) Chemical structures of scyllo-inositol and AAD-
66. The molecular weight of AAD-66 is about 10 times bigger than scyllo-inositol due to the six guanidine 
groups.
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familial AD mutations, and develops amyloid deposition at 2 months of age and the behavioral memory defi-
cits at 4–5 months of age21. Consistently, a spontaneous alternation deficit was detected in the 20-week-old Tg 
mice by Y-maze test (Fig. 2B). The Aβ deposits and gliosis were also detected in the 20-week-old Tg mice brains 
(Figs 3 and 4). After randomizing the 20-week-old Tg mice, AAD-66 or SI (0.3% in drinking water, 25–30mg/
day/mouse) was administered orally (ad libitum) to the mice for 10 weeks. The spontaneous alternation task 
on the Y-maze was examined again at 28 weeks (Fig. 2A). We found that both AAD-66 and SI treated Tg mice 
showed improved performance compared with the vehicle treated Tg mice, but a better result was observed with 
the AAD-66 treated Tg mice (Fig. 2C). The total number of individual arm entries was not significantly changed 
(Fig. 2D).
To further evaluate spatial memory functions, the Morris water maze (MWM) test was performed. During 
the training period, the spatial learning ability was not different among the four test groups (Fig. 1E). On the 6th 
day, the mice were given a probe trial in order to assess the spatial reference memory. AAD-66 treated Tg mice 
significantly improved their working memory as measured by longer target quadrant occupancy and more target 
Figure 2. AAD-66 more effectively rescues cognitive deficits in 5xFAD mice. (A) Experimental time course. 
(B) Cognitive deficits before administration evaluated by Y-maze tests. Unpaired t-test, NTg (n = 10), 
Tg (n = 30). (C,D) Y-maze test after 10-week administration. NTg(-) n = 10, Tg(-) n = 10, Tg(SI) n = 9, 
Tg(AAD-66) n = 10. (C) Percentage of alternation on the Y-maze after administration. (D) Total entry number 
into arms on the Y-maze. (E–H) Morris water maze test after administration. NTg(-) n = 10, Tg(-) n = 10, 
Tg(SI) n = 9, Tg(AAD-66) n = 10. (E) Escape latency in the Morris water maze plotted against the training days. 
(F) Percentage of time spent in the target and the opposite quadrant during a 60 sec probe trial on the day6.  
(G) Frequency of platform crossings during probe trial. (H) Swim speed of the probe test. All data are presented 
as mean ± SEM. One-way or two-way ANOVA followed by Tukey’s multiple comparisons test. *p < 0.05, 
**p < 0.01, ***p < 0.001.
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platform crossings comparable to the NonTg (NTg) control mice (Fig. 2F–H). The SI treated Tg mice also showed 
significant memory enhancement in the target quadrant occupancy (Fig. 2F), but the platform location crossings 
were not significantly rescued (Fig. 2G). Collectively, these results indicate that oral administration of AAD-66 
could effectively ameliorate the established cognitive deficits in 5xFAD mice and its efficacy was better than the 
SI treatment.
AAD-66 reduces Aβ deposits in the 5xFAD mice. After the behavioral tests described above, all mice 
were sacrificed at 30 weeks of age (Fig. 2A). The levels of the brain Aβ and plaque deposition were examined by 
biochemical extraction and analyses. SI was previously reported to reduce the amount of soluble Aβ in TgCRND8 
mice brains6. Therefore, we firstly examined whether the soluble Aβ was also reduced by AAD-66. Detergent-free 
TBS-soluble fractions were analyzed by filter-trap assay using 6E10 (for the total Aβ species) and A11 (for the Aβ 
soluble oligomers) antibodies as previously mentioned22. Both AAD-66 and SI reduced the levels of total Aβ and 
Aβ soluble oligomers in the detergent-free TBS-soluble fraction (Fig. 3A,B). As the molecular weight of AAD-66 
(1,684 g/mol) is about 10 times higher than SI (180 g/mol), the dosage of AAD-66 treated group at molar amount 
was about 10 times lower than the SI group, suggesting that AAD-66 has a substantial higher potency than SI 
(Fig. 1B).
Next, we examined the soluble oligomer species by Western blot analyses. It was found that both monomer 
and 4-meric oligomer species were significantly decreased by AAD-66 administration (Fig. 3C,D). The expres-
sion of the mutant human amyloid precursor protein (hAPP695) was not significantly altered by AAD-66 or SI 
administration (Fig. 3D). These observations indicate that AAD-66 effectively decreased the soluble Aβ species 
in 5xFAD mice brains to about the pre-administration (20w) levels.
Then, we further examined the soluble and insoluble Aβ42 levels by Aβ42 specific enzyme-linked immu-
nosorbent assay (ELISA) as the 5xFAD model is known to generate Aβ42 exclusively21. The soluble Aβ42 lev-
els in both AAD-66 and SI treated groups compared with the vehicle treated group showed a decreasing trend 
(p = 0.0692, p = 0.2451, respectively) (Fig. 3E). However, insoluble Aβ42 levels were significantly reduced by both 
AAD-66 and SI administration (Fig. 3F). These results are consistent with the previous report showing that SI 
resulted in a significant reduction in the insoluble Aβ42 levels, while the soluble Aβ42 levels did not show much 
reduction in the brains of the disease-established TgCRND8 mice6,7. Overall, our data suggest that both AAD-66 
Figure 3. AAD-66 reduces Aβ deposit and soluble oligomers in the 5xFAD mice brain. (A,B) Total Aβ and 
soluble oligomers in the detergent-free TBS-soluble fractions analyzed by filter-trap assay. (C,D) Western 
blot analysis for APP and Aβ species. GAPDH on the same membrane was labeled after membrane stripping. 
Synthetic Aβ42 was used for comparing Aβ monomer and oligomer size. (E,F) Soluble and insoluble Aβ42 levels 
measured by ELISA. (G,H) Effect of SI and AAD-66 efficacy on the negative correlation between pathobiology 
and behavioral function. The solid line represents linear regression of correlations of vehicle treated group. 
Number of mice for biochemical analyses: pre-administration (20w) n = 8, vehicle (30w) n = 10, SI (30w) n = 9, 
AAD-66 (30w) n = 10. All data are presented as mean ± SEM. One-way ANOVA followed by Tukey’s multiple 
comparisons test. *p < 0.05, **p < 0.01.
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and SI caused a reduction of the Aβ42 levels and AAD-66 demonstrated a higher Aβ42 reducing potency com-
pared to SI.
In addition, we examined the relationship between pathobiology and behavior function. The Aβ42 levels 
in the vehicle treated group negatively correlated with the alternation scores in Y-maze analysis (Fig. 3G,H). 
However, the SI or AAD-66 treated group did not show the correlation. It suggests that the treatment with SI or 
AAD-66 affected AD pathology in treated mice.
AAD-66 attenuates Aβ plaque accumulation and gliosis in the 5xFAD mice. We subsequently 
examined Aβ plaques in these treated Tg mice brains by immunohistochemistry using 6E10 antibody. A substan-
tial increase of plaque deposition was observed from 20 weeks to 30 weeks of age as measured by the brain area 
covered by Aβ plaques and the total plaque numbers (Fig. 4A–G). AAD-66 treatment resulted in a significant 
reduction in both the brain area covered by Aβ plaques and the total plaque numbers (34% and 21%, respec-
tively) compared with the vehicle treated Tg mice, reaching to a similar pathological condition as 20 weeks of age 
(Fig. 4F,G). These results demonstrate that AAD-66 administration successfully attenuated the increase of plaque 
number and accumulation in the diseased Tg mice brains.
Figure 4. AAD-66 lowers Aβ plaque deposits and gliosis in the 5xFAD mice brain. (A) 6E10-labeled Aβ 
plaques in sagittal sections of the brains. Scale bar, 1 mm. (B,C) Astrocytes and activated microglia with Aβ 
plaque deposition in the cortex (images were captured at the area above hippocampus). Scale bar, 100μm. (D,E) 
Astrocytes and activated microglia with Aβ plaque deposition in the hippocampus (images were captured at 
the area of dentate gyrus). Scale bar, 400, 100μm. (F,G) Quantified Aβ plaque deposition in the entire cortex 
area. Plaque covered area and number of plaques. (H,I) Astrogliosis and microgliosis levels quantified by GFAP 
and CD68 covered area in the entire cortex. pre-administration (20w) n = 8, vehicle (30w) n = 10, SI (30w) 
n = 9, AAD-66 (30w) n = 10. All data are presented as mean ± SEM. One-way ANOVA followed by Tukey’s 
multiple comparisons test. (#) p-values compared with pre-administration 20w Tg mice. (*) p-values compared 
with vehicle treated 30w Tg mice. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, #p < 0.05, ##p < 0.01, 
####p < 0.0001.
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It is generally known that the Aβ deposition accompanies aberrant inflammatory functions of astrocytes and 
microglia23. Aβ oligomers or aggregates in AD brains primarily bind to several receptors such as toll-like recep-
tors (TLRs) of astrocytes and microglia, and subsequently activate them24–27. These reactive responses result in 
abnormal proliferation or hypertrophy of glial cells, which is called gliosis28–30. SI was reported to reduce gliosis 
levels significantly in TgCRND8 mice6. Therefore, we examined astrogliosis and microgliosis by immunohisto-
chemistry using GFAP and CD68 antibodies, respectively. At 30 weeks of age, both astrogliosis and microgliosis 
were dramatically increased in mice brains compared with the 20-week-old age group, but the increments were 
significantly diminished by AAD-66 and SI administration (Fig. 4B–E,H,I), likely resulting from an attenuated 
plaque accumulation in the diseased brains. The effect of AAD-66 was again found to be substantially stronger 
than with SI.
Discussion
The preclinical and clinical studies of SI showed its potential benefits as a therapeutic agent for mild to moderate 
AD6,7,10,11. However, it was not approved for clinical use because of serious adverse effects and limited window of 
the dosage regime10,11. In the phase II clinical study, the administration of higher doses increased the CSF/brain 
concentrations of SI to the levels that were effective in animal models of AD, but the patients could not tolerate 
the doses10,11. The exact nature of the adverse effects has not been clearly defined, but the increased serum SI 
level is suspected to cause a dose-dependent decrease in uric acid, which indicates a renal function decline10,11. 
Thus, the clearance of systemically elevated SI might be impaired, and hyperuricemia might have occurred11,31. 
Hyperuricemia has been shown to represent a risk factor for exacerbating certain diseases such as gout, renal 
disease, cardiovascular disease, metabolic syndrome, urate lithiasis, atheroscleropathy, and hypertension. It was 
therefore suggested that the patients treated with higher concentrations of SI could be vulnerable to these disor-
ders11. We have hypothesized that if the delivery efficiency of SI into the brain could be enhanced by applying our 
guanidine-appended modification strategy, we might be able to expect a good therapeutic efficacy even at lower 
concentration levels, thus minimizing the adverse effects.
The present study shows that the oral administration of AAD-66 significantly reduced AD-like cognitive defi-
cits and neuropathology in the disease-established 5xFAD mice. A preliminary study carried out with a different 
AD mouse model, Tg2576 showed comparable results to a key portion of the present results. When 9 months old 
Tg mice were treated with AAD-66 (25–30 mg/day/mouse) ad libitum for 3 months, the hippocampal Aβ40 and 
Aβ42 were decreased by 37, 26, 44, and 32% for Aβ40 (soluble and insoluble) and Aβ42 (soluble and insoluble), 
respectively, compared with the vehicle treated Tg2576 mice (Supplementary Table S1).
AD therapies are expected to require a long-term treatment with therapeutic agents. In this connection, the 
toxicity profile of the therapeutic agent may be a critical consideration in evaluating therapeutic potentials. We 
have carried out in a preliminary fashion some toxicology studies of AAD-66 in terms of cytotoxicity in a number 
of cell lines, cytochrome P450 (CYP) activity, cardiac hERG K+ channel binding, and single dose in vivo toxicity, 
and also plasma protein binding rate and metabolic stability, which showed no unusual features (Supplementary 
Tables S2–S5 and Supplementary Figs S2 and S3). The AAD-66 concentration levels used in the present study, 
30mg/day/mouse and 10 μM for cells, were well below the levels at which the toxicity studies were undertaken. 
In the Tg mice study, each mouse was given the same weight amount of SI or AAD-66. The molecular weight of 
AAD-66 is about 10 times higher than that of SI due to the guanidine-appended modifications (Fig. 1B). Thus, 
the in-take molar quantity of AAD-66 was about 10 times lower than that of SI, although substantially improved 
efficacies were generally observed for AAD-66 on the AD phenotypes compared with SI itself.
The results obtained in the present study are in general accord with the previous studies on the SI effects in 
TgCRND8 mice6,7. The mode of action of AAD-66 may be presumed to be similar to that of SI, although it is not 
clear at the moment whether the observed beneficial activity is due to the intact AAD-66 molecule or its various 
hydrolyzed products, structurally resembling SI. Overall, the present study shows that substance AAD-66 can 
inhibit plaque growth or formation possibly by interfering with growth of aggregates and fibers, or by cap-off the 
growing edges of the Aβ aggregates as SI has been proposed to do7.
A sustained elevated level of SI in the brain was proposed to be beneficial and necessary for the AD treat-
ment6,7. A significant amount of SI is not likely to cross the BBB or cellular membranes by a diffusion process 
based on its chemical structure. The observation that the SI level in the brain is 100 times higher than in the 
periphery, indicates an active transport for SI in the brain must be involved32. Recently, two transporters, SMIT-1 
and SMIT-2, have been identified to transport scyllo-inositol into the brain33,34. As the levels of transporters are 
not altered with AD pathology33, achieving the effective levels of SI in the brain was possible only with high doses 
in the phase II clinical study. Thus the dilemma is that the high doses are necessary but it causes serious adverse 
effects10,11. It implies that the delivery efficiency into the brain could be a critical issue when patients are treated 
with SI. Thus, we suggest that one way of overcoming the delivery problem of SI is to utilize a viable delivery sys-
tem, in particular, the BBB-permeable guanidine-appended modifications as demonstrated in the present study. 
Although there might be other possible strategies to overcome the BBB, at the present time our simple strategy 
appears practical and should find some utilities in combating AD. In conclusion, further development of AAD-66 
as a therapeutic agent for AD would be potential and promising.
Methods
Synthesis of scyllo-inositol derivatives. Chemical synthesis methods are included in Supplementary 
Methods.
Mice. Generation of 5xFAD mice (Tg6799) was previously described21. Briefly, 5xFAD mice have transgenes 
that include five familial Alzheimer’s disease (FAD) mutations including the K670N/M671L (Swedish), I716V 
(Florida), and V717I (London) mutations in the 695 amino acids isoform of the human amyloid precursor 
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protein (APP695), as well as M146L and L286V mutations in human presenilin-1 (PS1). The transgenes are under 
the control of the murine Thy-1 promoter. The male transgenic mice were bred with B6/SJL hybrid female mice 
and the genotypes were determined by PCR analysis of tail cut samples. The nontransgenic littermates were used 
as control animals and only male mice were used in this study.
Approval of the study protocol was obtained from the Pohang University of Science and Technology 
Institutional Animal Care and Use Committee (POSTECH IACUC) (Approval ID: POSTECH-2016–0026). All 
animal experiments were carried out according to the provisions of the Animal Welfare Act, PHS Animal Welfare 
Policy, and the principles of the NIH Guide for the Care and Use of Laboratory Animals. All mice were main-
tained under conventional conditions at POSTECH animal facility under institutional guidelines.
Oral Administration. scyllo-Inositol (TCI, I0631) or AAD-66 in drinking water was freely administered ad 
libitum to 20-week-old 5xFAD Tg mice for 10 weeks. Saccharin salt in water (1%) was used for vehicle to mitigate 
the bitterness of AAD-66. The 1% saccharin-treated NTg (n = 10) and Tg (n = 10) mice were used for the control 
groups. scyllo-Inositol (0.3%) or AAD-66 (0.3%) in 1% saccharin solution was used for experimental groups 
(n = 9, n = 10, respectively). Water consumptions were monitored every couple of days and the drug containing 
waters were exchanged freshly every four to five days. Drug concentrations in the drinking water were recalcu-
lated and set according to the monitored water consumption.
Y-maze test. The Y-maze apparatus has V-shaped three arms (40 × 3 × 12 cm) at 120° angles from each 
other. For the spontaneous Y-maze alternation test, mice were placed at the end of one arm and allowed to freely 
explore the maze during 8 min under the dim light conditions (50 lux). If the mouse has an intact short-term 
spatial working memory, it would show a tendency to enter the arm that is different from those recently visited. 
Alternation was defined as a consecutive entry in three different arms. The number and the sequence of individual 
arm visits were recorded and alternation percentage was calculated.
Morris water maze (MWM). The water maze tank (120 cm diameter) was filled with water. White non-toxic 
tempera paint was used to make the water opaque. Four different visual cues were seen each cardinal points. The 
water temperature was set around 22 °C before the experiments. Four trials (60 sec each, 30 min intervals) were 
performed per day during the training. The visible platform test was performed on Day 0 and the hidden platform 
training was performed for five consecutive days. The probe trial was performed on Day 6. The trajectories were 
recorded with a video tracking system (SMART v2.5, Panlab).
Protein extraction. To better identify proteins of interest, we used three different extraction protocols 
serially to isolate proteins. First, the hemi-brain samples were weighed and homogenized at 100 mg/ml in 
detergent-free TBS with protease inhibitor cocktail (Sigma, P8340). The homogenates were divided into two 
tubes, one for the detergent-free TBS-soluble fraction for filter-trap analysis and the second one for the serial 
extraction.
To prepare the detergent-free TBS-soluble fraction for the filter-trap analysis, the detergent-free TBS homoge-
nates were centrifuged at 15,000 rpm for 30 min at 4 °C. The supernatants were used immediately.
To prepare the soluble fraction for the Western blot analysis and ELISA, the detergent-free TBS homogenates 
were sonicated and centrifuged at 15,000 rpm for 1hr at 4 °C. The supernatants were stored at −80  °C until further 
use. The pellets were reserved for the extraction of insoluble proteins.
To prepare the insoluble fraction for ELISA, the pellets obtained above were dissolved in 70% formic acid and 
vigorously shaken until all pellets got dissolved completely. After centrifugation at 15,000 rpm for 1hr at 4 °C, the 
supernatants were stored at −80 °C until further use. Before analysis, the insoluble fraction samples were neutral-
ized by adding 1:20 volume of neutralization buffer (1 M Tris, 0.5 M NaH2PO4).
Filter-trap analysis. The detergent-free TBS-soluble fraction samples for the filter-trap analysis (4 μg) were 
loaded on nitrocellulose membranes using the Bio-Dot® microfiltration apparatus (BIO-RAD) and filtered under 
vacuum. The membranes were dried and followed by blocking with 10% skim milk. Primary antibodies, A11 
(1:2,000, AHB0052), 6E10 (1:2,000, SIG39320), and secondary antibodies (1:5,000) were used for detecting solu-
ble oligomers and total Aβ, respectively.
Western blot analysis. The soluble fraction samples (30 μg) were separated by SDS-PAGE on 16% Tricine 
gels and transferred to nitrocellulose membranes (200 mA constant for 2hr, wet transfer). The membranes were 
labeled with primary antibodies, 6E10 (1:1,000, SIG39320), GAPDH (1:2,000, MAB374), for overnight at 4 °C and 
then labeled with the HRP-conjugated secondary antibodies (1:5,000). Chemiluminescence images were captured 
by ImageQuant LAS 4000 (Fuji).
ELISA. Commercially available Aβ42 sandwich ELISA kits (Invitrogen, KHB3442) were used for analyzing the 
soluble and insoluble Aβ42 levels. The soluble fraction samples were diluted in the ratio of 1:200 and the insoluble 
fraction samples were firstly neutralized using neutralization buffer in the ratio of 1:20 and diluted further to in 
the ratio of 1:500 in the ELISA diluent buffer. The experiment was performed as the manufacturer’s protocol. 
Synthetic Aβ42 peptide in the assay kit was used for standard curve (y = 67.626x2 + 240.72x + 4.8938).
Immunohistochemistry. Sagittal cryo-sections (20 μm) of the perfused mice hemi-brains were used for 
immunohistochemistry. Antigen retrieval was performed by boiling for 20 min in sodium citrate buffer (10 mM 
sodium citrate in H2O, pH 6.0). For Aβ plaque, the sections were additionally soaked in 88% formic acid for 
5 min. The sections were blocked with a blocking solution (5% FBS, 3% BSA, 0.3% Triton X-100 in PBS) for 1hr 
at room temperature, and then labeled with primary antibodies, 6E10 (1:300, SIG39320), GFAP (1:500, ab7260), 
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CD68 (1:200, ab125212), in the blocking solution overnight at 4 °C. The sections were labeled with Alexa-488 or 
-594 linked secondary antibodies (1:1,000) for 1hr at room temperature followed by nucleus stain with Hoechst 
(1 μg/ml) for 10 min. The sections were finally mounted with Dako fluorescence mounting medium.
Imaging was performed using Nikon and ZEISS fluorescent microscopes. The area of Aβ plaques and gliosis 
in the entire cerebral cortex were analyzed by the “Analyze Particles” function of ImageJ program. Evenly spaced 
8–10 sections per mouse were analyzed for Aβ plaques and 5–6 sections per mouse were analyzed for each gliosis. 
The average percentage of the analyzed area was calculated.
Statistical Analysis. All statistical analyses were performed using GraphPad Prism version 6.0. The signif-
icance of differences was assessed by the unpaired Student’s t test or one- or two-way ANOVA followed by the 
Tukey’s multiple comparison tests. A p-value of p < 0.05 was considered to represent a significance. All data are 
presented as mean ± SD or SEM.
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